This post was originally published on this site
FRANKFURT (Reuters) – Merck KGaA’s drug development programme has suffered a setback with the most important clinical trial of its cancer drug hopeful bintrafusp alfa stopped because the treatment does not appear to work.
The halt also puts a damper on the oncology ambitions of Britain’s GlaxoSmithKline (NYSE:GSK), which is co-developing the drug with Merck under a 2019 agreement that could have seen it pay up to 3.7 billion euros ($4.5 billion) to the German company.
In a statement on Wednesday, Merck KGaA said the late-stage trial dubbed INTR@PID Lung 037, testing the novel drug against U.S. namesake Merck & Co’s bestseller Keytruda in newly diagnosed cases of a certain type of lung cancer, would be discontinued.
It said independent supervisors concluded the drug was unlikely to show the desired efficacy.
Merck KGaA’s shares dropped as much as 7% but had pared losses to trade 3.3% lower at 1355 GMT.
Keytruda dominates a class of immunotherapies known as checkpoint inhibitors, and is expected to generate $17 billion in revenues this year.
Merck KGaA and Merck & Co Inc, known as MSD outside North America, share historic roots but have been under separate ownership since World War One.
The bintrafusp alfa drug is a so-called fusion protein designed to trigger both checkpoint inhibition and another immune response booster known as TGF-beta-inhibtion.
While several other experimental drugs are based on TGF-beta-inhibtion, the combination is a unique approach in the pharma industry.
($1 = 0.8264 euros)
